Savara Inc Net Income (Loss) Available to Common Stockholders, Diluted
Savara Inc (SVRA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$40.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-11
- Savara Inc net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$40.23M.
- Savara Inc net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$37.28M.
- Savara Inc net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$32.24M.
- Savara Inc net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$29.56M.
- Savara Inc net income (loss) available to common stockholders, diluted for fiscal 2025 was -$118.84M.
- Savara Inc net income (loss) available to common stockholders, diluted for fiscal 2024 was -$95.88M.
- Savara Inc net income (loss) available to common stockholders, diluted for fiscal 2023 was -$54.70M.
- Savara Inc net income (loss) available to common stockholders, diluted for fiscal 2022 was -$38.15M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$40.23M 10-Q · filed 2026-08-11 | -$77.51M 10-Q · filed 2026-08-11 | -$109.75M derived: sum of 3 quarters · filed 2026-08-11 | -$139.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$37.28M 10-Q · filed 2026-05-12 | -$69.52M derived: sum of 2 quarters · filed 2026-05-12 | -$99.08M derived: sum of 3 quarters · filed 2026-05-12 | -$129.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$32.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$61.80M derived: sum of 2 quarters · filed 2026-03-13 | -$92.20M derived: sum of 3 quarters · filed 2026-08-11 | -$118.84M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$29.56M 10-Q · filed 2025-11-12 | -$59.96M derived: sum of 2 quarters · filed 2026-08-11 | -$86.60M 10-Q · filed 2025-11-12 | -$115.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$30.40M 10-Q · filed 2026-08-11 | -$57.04M 10-Q · filed 2026-08-11 | -$86.08M derived: sum of 3 quarters · filed 2026-08-11 | -$110.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$26.64M 10-Q · filed 2026-05-12 | -$55.68M derived: sum of 2 quarters · filed 2026-05-12 | -$79.93M derived: sum of 3 quarters · filed 2026-05-12 | -$102.17M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$29.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$53.29M derived: sum of 2 quarters · filed 2026-03-13 | -$75.53M derived: sum of 3 quarters · filed 2026-03-13 | -$95.88M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$24.25M 10-Q · filed 2025-11-12 | -$46.49M derived: sum of 2 quarters · filed 2025-11-12 | -$66.84M 10-Q · filed 2025-11-12 | -$82.94M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$22.24M 10-Q · filed 2025-08-13 | -$42.59M 10-Q · filed 2025-08-13 | -$58.69M derived: sum of 3 quarters · filed 2025-08-13 | -$75.29M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$20.35M 10-Q · filed 2025-05-13 | -$36.45M derived: sum of 2 quarters · filed 2025-05-13 | -$53.04M derived: sum of 3 quarters · filed 2025-05-13 | -$64.49M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$16.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$32.70M derived: sum of 2 quarters · filed 2025-03-27 | -$44.14M derived: sum of 3 quarters · filed 2025-03-27 | -$54.70M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$16.60M 10-Q · filed 2023-11-09 | -$28.04M derived: sum of 2 quarters · filed 2024-08-12 | -$38.60M 10-Q · filed 2023-11-09 | -$48.90M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-06-30 | -$11.44M 10-Q · filed 2024-08-12 | -$22.00M 10-Q · filed 2024-08-12 | -$32.30M derived: sum of 3 quarters · filed 2024-08-12 | -$42.69M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$10.56M 10-Q · filed 2024-05-09 | -$20.86M derived: sum of 2 quarters · filed 2024-05-09 | -$31.24M derived: sum of 3 quarters · filed 2024-05-09 | -$40.41M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$20.69M derived: sum of 2 quarters · filed 2024-03-07 | -$29.85M derived: sum of 3 quarters · filed 2024-03-07 | -$38.15M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$10.39M 10-Q · filed 2023-11-09 | -$19.55M derived: sum of 2 quarters · filed 2023-11-09 | -$27.85M 10-Q · filed 2023-11-09 | -$39.16M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$9.16M 10-Q · filed 2023-08-10 | -$17.46M 10-Q · filed 2023-08-10 | -$28.77M derived: sum of 3 quarters · filed 2023-08-10 | -$39.32M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$8.30M 10-Q · filed 2023-05-15 | -$19.61M derived: sum of 2 quarters · filed 2023-05-15 | -$30.16M derived: sum of 3 quarters · filed 2023-05-15 | -$41.10M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$11.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$21.86M derived: sum of 2 quarters · filed 2023-03-30 | -$32.80M derived: sum of 3 quarters · filed 2023-03-30 | -$43.01M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$10.55M 10-Q · filed 2022-11-10 | -$21.49M derived: sum of 2 quarters · filed 2022-11-10 | -$31.70M 10-Q · filed 2022-11-10 | -$45.45M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$10.94M 10-Q · filed 2022-08-11 | -$21.16M 10-Q · filed 2022-08-11 | -$34.90M derived: sum of 3 quarters · filed 2022-08-11 | -$45.96M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$10.22M 10-Q · filed 2022-05-11 | -$23.96M derived: sum of 2 quarters · filed 2022-05-11 | -$35.02M derived: sum of 3 quarters · filed 2022-05-11 | -$44.41M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$24.80M derived: sum of 2 quarters · filed 2022-03-30 | -$34.19M derived: sum of 3 quarters · filed 2022-03-30 | -$49.62M 10-K · filed 2022-03-30 |
| 2020-09-30 | -$11.06M 10-Q · filed 2021-11-12 | -$20.45M derived: sum of 2 quarters · filed 2021-11-12 | -$35.87M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$9.39M 10-Q · filed 2021-08-12 | -$24.81M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$15.42M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |